Nephrotic syndrome: Efficacy of rituximab in challenging nephrotic syndrome.
A new trial provides further evidence that rituximab treatment can reduce the risk of relapse in children with steroid-dependent idiopathic nephrotic syndrome. Addition of a single infusion of rituximab to steroid therapy was associated with a decrease in proteinuria at 3 months and a significant increase in the relapse-free period.
Division of Paediatric Nephrology, Children's Hospital Los Angeles, University of Southern California, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA.
Kevin V
KV
Lemley
Division of Paediatric Nephrology, Rady Children's Hospital, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0630, USA.
Robert H
RH
Mak
D005260:Female; D006801:Humans; D008297:Male; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D007155:Immunologic Factors / Q000627:therapeutic use; D009404:Nephrotic Syndrome / Q000188:drug therapy; D011241:Prednisone / Q000009:adverse effects; D000069283:Rituximab / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
D000893:Anti-Inflammatory Agents; D007155:Immunologic Factors; D011241:Prednisone; D000069283:Rituximab